focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,983.00
Bid: 1,990.00
Ask: 1,991.00
Change: -45.00 (-2.22%)
Spread: 1.00 (0.05%)
Open: 2,030.00
High: 2,034.00
Low: 1,980.00
Prev. Close: 2,028.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 08th Jul 2013 08:48

Anglo American: Exane reduces target price from 1700p to 1400p and reiterates its underperform rating.Anite Group: Investec raises target price from 135p to 155p and upgrades from hold to buy.Ashmore Group: RBC Capital Markets takes target price from 440p to 375p and keeps its neutral rating.Balfour Beatty: Bank of America cuts target price from 255p to 240p and downgrades to neutral.Bovis Homes Group: Jefferies ups target price from 897p to 909p keeping a buy recommendation. Panmure Gordon raises target price from 660p to 714p and retains a hold recommendation.Escher Group: Panmure Gordon moves target price from 459p to 465p reiterating a buy recommendation.Fidessa: Sanlam Securities increases target price from 2000p to 2340p and stays with a buy recommendation.Hikma Pharmaceuticals: HSBC Holdings raises target price from 745p to 1035p, while retaining a neutral rating. Panmure Gordon takes target price from 1000p to 1100p and leaves its buy recommendation unaltered.Interserve: Westhouse Securities ups target price from 537p to 582p keeping an add rating.Investec: Morgan Stanley lowers target price from 525p to 500p and maintains an overweight rating.Petropavlovsk: Goldman Sachs revises target price from 106p to 76p and keeps its sell recommendation.Polymetal International: HSBC Holdings reduces target price from 1000p to 620p, while leaving its overweight rating unchanged. Goldman Sachs cuts target price from 800p to 340p downgrading from neutral to sell.Polyus Gold International: Goldman Sachs moves target price from 230p to 210p leaving its neutral rating unaltered.Restaurant Group: JP Morgan increases target price from 525p to 565p and reiterates an overweight rating.Spirent Communications: Goldman Sachs shifts target price from 164p to 160p, but leaves its buy recommendation unchanged.Synergy Health: Investec downgrades from buy to add with a target price of 1170p.Vodafone: Credit Suisse moves target price from 180p to 195p and retains an outperform rating.Young & Co's Brewery: JP Morgan takes target price from 840p to 910p and stays with its overweight rating.
More News
27 Sep 2021 09:31

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

Read more
27 Sep 2021 09:28

UPDATE 2-Energy stocks, banks lift FTSE 100; Rolls-Royce top performer

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rolls-Royce jumps on sales of Spain-based ITP, U.S. Air Force contract* Energy stocks track crude oil prices higher* Hikma Pharma gains o...

Read more
27 Sep 2021 08:50

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

Read more
27 Sep 2021 08:16

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

Read more
27 Sep 2021 07:49

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
13 Sep 2021 16:09

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
2 Sep 2021 09:38

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

Read more
27 Aug 2021 12:32

Hikma, Bio-Thera enter exclusive agreement for monoclonal antibody

(Sharecast News) - Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monoclonal antibody used for the treatment of Crohn's disease.

Read more
20 Aug 2021 09:46

LONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold

LONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold

Read more
20 Aug 2021 08:10

LONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons

LONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons

Read more
17 Aug 2021 09:46

UPDATE 2-Energy, healthcare stocks lift FTSE 100; BHP Group shines

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK employment closer to pre-pandemic levels* BHP Group jumps on strong results* PLUS500 gains on robust revenue forecasts* FTSE 100 up 0.3%...

Read more
12 Aug 2021 16:04

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
6 Aug 2021 17:06

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.